XML 29 R16.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Liability Related to the Sale of Future Royalties | 12 Months Ended
--- | ---
Dec. 31, 2016
Liability Related To Sale Of Potential Future Royalties [Abstract] |
Liability Related to Sale of Future Royalties | Note 7 — Liability Related to the Sale of Future Royalties On February 24, 2012, we entered into a Purchase and Sale Agreement (the Purchase and Sale Agreement) with RPI Finance Trust (RPI), an affiliate of Royalty Pharma, pursuant to which we sold, and RPI purchased, our right to receive royalty payments (the Royalty Entitlement) arising from the worldwide net sales, from and after January 1, 2012, of (a) CIMZIA®, under our license, manufacturing and supply agreement with UCB Pharma (UCB), and (b) MIRCERA®, under our license, manufacturing and supply agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together referred to as Roche). We received aggregate cash proceeds of $124.0 million for the Royalty Entitlement. As part of this sale, we incurred approximately $4.4 million in transaction costs, which will be amortized to interest expense over the estimated life of the Purchase and Sale Agreement. Although we sold all of our rights to receive royalties from the CIMZIA® and MIRCERA® products, as a result of our ongoing manufacturing and supply obligations related to the generation of these royalties, we will continue to account for these royalties as revenue and we recorded the $124.0 million in proceeds from this transaction as a liability (Royalty Obligation) that will be amortized using the interest method over the estimated life of the Purchase and Sale Agreement. The following table shows the activity within the liability account during the year ended December 31, 2016 and for the period from the inception of the royalty transaction on February 24, 2012 (inception) to December 31, 2016 (in thousands):
|  | Year ended December 31, 2016 |  |  | Period from inception to December 31, 2016 |
Liability related to the sale of future royalties—beginning balance |  | $ | 119,032 |  |  | $ | — |
Proceeds from sale of future royalties |  |  | — |  |  |  | 124,000 |
Payments from Nektar to RPI |  |  | — |  |  |  | (10,000 | )
Non-cash CIMZIA® and MIRCERA® royalty revenue |  |  | (30,158 | ) |  |  | (106,999 | )
Non-cash interest expense recognized |  |  | 19,712 |  |  |  | 101,585 |
Liability related to the sale of future royalties – ending balance |  |  | 108,586 |  |  |  | 108,586 |
Less: unamortized transaction costs |  |  | (2,636 | ) |  |  | (2,636 | )
Liability related to the sale of future royalties, net |  | $ | 105,950 |  |  | $ | 105,950 |
Pursuant to the Purchase and Sale Agreement, in March 2014 and March 2013, we were required to pay RPI $7.0 million and $3.0 million, respectively, as a result of worldwide net sales of MIRCERA® for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds. The Purchase and Sale Agreement does not include any other potential payments related to minimum net sales thresholds and, therefore, we do not expect to make any further payments to RPI related to this agreement. During the years ended December 31, 2016, 2015 and 2014, we recognized $30.2 million, $22.1 million, and $21.9 million, respectively, in non-cash royalties from net sales of CIMZIA® and MIRCERA® and we recorded $19.7 million, $20.6 million and $20.9 million, respectively, of related non-cash interest expense. As royalties are remitted to RPI from Roche and UCB, the balance of the Royalty Obligation will be effectively repaid over the life of the agreement. In order to determine the amortization of the Royalty Obligation, we are required to estimate the total amount of future royalty payments to be received by RPI. The sum of these amounts less the $124.0 million proceeds we received will be recorded as interest expense over the life of the Royalty Obligation. Since inception, our estimate of this total interest expense resulted in an effective annual interest rate of approximately 17%. We periodically assess the estimated royalty payments to RPI from UCB and Roche and to the extent the amount or timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the Royalty Obligation. There are a number of factors that could materially affect the amount and timing of royalty payments from CIMZIA® and MIRCERA®, most of which are not within our control. Such factors include, but are not limited to, changing standards of care, the introduction of competing products, manufacturing or other delays, biosimilar competition, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to RPI are made in U.S. dollars (USD) while significant portions of the underlying sales of CIMZIA® and MIRCERA® are made in currencies other than USD, and other events or circumstances that could result in reduced royalty payments from CIMZIA® and MIRCERA®, all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Obligation. Conversely, if sales of CIMZIA® and MIRCERA® are more than expected, the non-cash royalty revenues and the non-cash interest expense recorded by us would be greater over the term of the Royalty Obligation. In addition, the Purchase and Sale Agreement grants RPI the right to receive certain reports and other information relating to the Royalty Entitlement and contains other representations and warranties, covenants and indemnification obligations that are customary for a transaction of this nature. To our knowledge, we are currently in compliance with these provisions of the Purchase and Sale Agreement; however, if we were to breach our obligations, we could be required to pay damages to RPI that are not limited to the purchase price we received in the sale transaction.

X
- Definition Liability related to sale of potential future royalties. + References No definition available. + Details
Name: | nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesAbstract
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability related to sale of potential future royalties. + References No definition available. + Details
Name: | nktr_LiabilityRelatedToSaleOfPotentialFutureRoyaltiesTextBlock
Namespace Prefix: | nktr_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration